Maibach, Howard Katzenstein, Giorgio Perilongo, Daniel C. Aronson, Dietrich VonSchweinitz, Rebecka L. Meyers. Hepatocellular carcinoma in children and Adolescents:The international Therapeutic experience. 43th APSA Annual Meeting APSA-IPSO SYMPOSIUM. TEXAS, USA. MAY 19 – 20, 2012.

10) Hiyama E, Kamimatsuse A, Ogura K, Ueda Y, Hiyama K. Next-generation sequencing: Integrated exotome analysis in human multiple neuroblastoma. ANR2012. Tronto. June 19, 2012.

11) Hiyama E, Kamimatsuse A, Ueda Y, Ogura K, Sueda T, Hiyama K. Identification of new candidate biomarkers in progression of neuroblastoma cells using differential transcriptome and proteome analysis. ANR2012. Tronto. June 20, 2012.

12) Yoneda A, Tajiri T, Hishiki T, Maeda K, iehara T, Hiyama E. Changes in clinical feature of neuroblastoma after the cessation of the mass screening in Japan -Analysis of the Neuroblastoma registry data of the Tumor committee of the Japanese Society of Pediatric Surgeons-. ANR2012. Tronto. June 20, 2012.

13) 檜山英三. 小児固形腫瘍の最近の話題. 国立病院機構福山医療センターオープンカンファレンス. 広島県福山市. 2012年8月31日.

14) 檜山英三. 小児肝腫瘍の最近の話題. 第36回北陸小児癌症例検討会. 石川県金沢市. 2012年9月15日.

15) Ueda Y, Kamimatsuse A, Ogura K, Onitake Y, Hiyama K, Hiyama E. Echanism of Wnt signal pathway activation in hepatoblastoma. SIOP2012. London. October6, 2012.

16) Kawashima M, Hiyama E, Kamei N, Kamimatsuse A, Ueda Y, Ogura K, Hiyama K. ALK activating infant neuroblastoma cases including mass-screening detected cases. SIOP2012. London. October6, 2012.

17) Hiyama E. A genome-wide association study identifies new candidate loci associated with progression of hepatoblastoma in JPLT2 study experience. SIOP2012. London. October 6, 2012.

18) 檜山英三. 小児がんにおける国際共同臨床試験の基盤整備と新薬導入への対応策の検討. 第19回ヘルスリサーチフォーラム. 東京都. 2012年11月10日.

19) 本多昌平、岡田忠雄、宮城久之、春田雅之、金子安比古、檜山英三、武富紹信. 肝芽腫メチル化解析による予後予測マーカーの確立. 第23回日本消化器癌発生学会総会. 徳島県鳴門市. 2012年11月16日.

20) 米田光宏, 田尻達郎, 菱木知郎, 近藤知史, 杉山正彦, 水田耕一, 亀井尚美, 木下義晶, 平山裕, 脇坂宗親, 佐々木文章, 本多昌平, 佐藤智行, 塚田真実, 仲谷健吾, 大植孝治, 上松瀬新, 家原知子, 檜山英三, 前田貢作. マススクリーニング休止による本邦神経芽腫像の変化—小児外科学会悪性腫瘍登録データの解析より—. 第54回日

本小児血液がん学会学術集会. 横浜市. 2012年11月30日.

21) 鬼武美幸, 檜山英三, 小倉薫, 上松瀬新, 上田祐華, 村上義昭, 上村健一郎, 北山保博. 膵solid pseudopapillary tumorの1例. 第54回日本小児血液がん学会学術集会. 横浜市. 2012年11月30日. 2012年12月1日.

H. 知的財産権の出願・登録状況
(予定を含む)

1. 特許出願 なし
2. 実用新案登録 なし
3. その他 なし

研究成果の刊行に関する一覧

別紙4
雑誌

発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
Hachiya Y, Hayashi M, Negishi T, Atsumi S, Kubota M, Nishihara T.	A Case of Osteogenesis Imperfecta Type II Caused by a Novel *COL1A2* Gene Mutation: Endoscopic Third Ventriculostomy to Prevent Hydrocephalus	Neuropediatrics	43	225-228	2012
Higashimoto K, Nakabayashi K, Yatsuki H, Yoshinaga H, Jozaki K, Okada J, Watanabe Y, Aoki A, Shiozaki A, Saito S, Koide K, Mukai T, Hata K, Soejima H.	Aberrant methylation of H19-DMR acquired after implantation was dissimilar in soma versus placenta of patients with Beckwith-Wiedemann syndrome.	Am J Med Genet A.	158A	1670-1675	2012
Lee H, Kashiwakura J, Matsuda A, Watanabe Y, Sakamoto-Sasaki T, Matsumoto K, Hashimoto N, Saito S, Ohmori K, Nagaoka M, Tokuhashi Y, Ra C, Okayama Y.	Activation of human synovial mast cells from rheumatoid arthritis or osteoarthritis patients in response to aggregated IgG through FceRI and FcgRII.	Arthritis Rheum.	65	109-119	2012
Shigeta N, Ozaki K, Hori K, Ito K, Nakayama M, Nakahira K, Yanagihara I.	An Arthrobacter spp. Bacteremia Leading to Fetal Death and Maternal Disseminated Intravascular Coagulation.	Fetal and Pediatric Pathology	32	25-31	2013
Namba F, Ina S, Kitajima H, Yoshio H, Mimura K, Saito S, Yanagihara I.	Annexin A2 in amniotic fluid: Correlation with histological chorioamnionitis, preterm premature rupture of membranes, and subsequent preterm delivery.	J Obstet Gynaecol Res.	38(1)	137-144	2012

別紙4
雑誌

Morita H, Nomura I, Orihara K, Yoshida K, Akasawa A, Tachimoto H, Ohtsuka Y, Namai Y, Futamura M, Shoda T, Matsuda A, Kamemura N, Kido H, Takahashi T, Ohya Y, Saito H, Matsumoto K	Antigen-specific T-cell responses in patients with non-IgE-mediated gastrointestinal food allergy are predominantly skewed to T(H)2	J Allergy Clin Immunol		In Press	2012
Matsuda A, Morita H, Unno H, Saito H, Matsumoto K, Hirao Y, Munechika K, Abe J	Anti-inflammatory effects of high-dose IgG on TNF-alpha-activated human coronary artery endothelial cells	Eur J Immunol	42(8)	2121-2131	2012
Darmochwal-Kolarz D., Saito S., Tabarkiewicz J., Kolarz B., Rolinski J., Leszczynska-gorzelak B., Oleszczuk J.	Apoptosis Signaling Is Altered in CD4+CD25+FoxP3+ T Regulatory Lymphocytes in Pre-Eclampsia.	Int. J. Mol. Sci.	13	6548-6560	2012
Shigeta N, Ozaki K, Hori K, Ito K, Nakayama M, Nakahira K, Yanagihara I.	*Arthrobacter* spp. bacteremia leading to fetal death and maternal disseminated intravascular coagulation.	Fetal and Pediatric Pathology	32	25-31	2013
Hayashi M, Saito-Miwa N, Tanuma N, Kubota M.	Brain vascular change in Cockayne syndrome.	Neuropathogy	32	113-117	2012

別紙4
雑誌

Iglesias-Platas I, Martin-Trujillo A, Cirillo D, Court F, Guillaumet-Adkins A, Camprubi C, Bourc'his D, Hata K, Feil R, Tartaglia G, Arnaud P, Monk D.	Characterization of novel paternal ncRNAs at the Plagl1 locus, including Hymai, predicted to interact with regulators of active chromatin.	PLoS One.	7(6)	e38907	2012
Ogura T, Hiyama E, Kamei N, Kamimatsuse A, Ueda Y, Ogura K.	Clinical feature of ALK mutated neuroblastoma	Journal of Pediatric Surgery	47(10)	1789-1796	2012
Shiozaki A, Matsuda Y, Satoh S, Saito S.	Comparison of risk factors for gestational hypertension and preeclampsia in Japanese singleton pregnancies.	JOGR		in press	2012
Kobayashi H, Sakurai T, Imai M, Takahashi N, Fukuda A, Yayoi O, Sato S, Nakabayashi K, Hata K, Sotomaru Y, Suzuki Y, Kono T.	Contribution of intragenic DNA methylation in mouse gametic DNA methylomes to establish oocyte-specific heritable marks.	PLoS Genet.	8(1)	e1002440	2012
Li LP, Fang YC, Dong GF, Lin Y, Saito S.	Depletion of Invariant NKT Cells Reduces Inflammation-Induced Preterm Delivery in Mice.	J Immunol.	188	4681-4689	2012
Kinoshita M, Numata S, Tajima A, Shimodera S, Ono S, Imamura A, Iga JI, Watanabe S, Kikuchi K, Kubo H, Nakataki M, Sumitani S, Imoto I, Okazaki Y, Ohmori T.	DNA methylation signatures of peripheral leukocytes in schizophrenia.	Neuromolecular Med			in press

Sakamoto S, Wakae K, Anzai Y, Murai K, Tamaki N, Miyazaki M, Miyazaki K, Romanow WJ, Ikawa T, Kitamura D, Yanagihara I, Minato N, Murre C, Agata Y.	E2A and CBP/p300 Act in synergy to promote chromatin accessibility of the immunoglobulin κ locus	J Immunol	188(11)	5547-60	2012
Fujishima H, Satake Y, Okada N, Kawashima S, Matsumoto K, Saito H	Effects of diesel exhaust particles on primary cultured healthy human conjunctival epithelium	Ann Allergy Asthma Immunol	110(1)	39-43	2013
Horikawa R.	Endocrine disease: progress in diagnosis and treatment. Topics: I. Progress in diagnosis; 5. Gonad: clinical approach to disorder of sex development (DSD)	Nihon Naika Gakkai Zasshi.	101(4)	965-974	2012
Hoshino A, Saitoh M, Oka A, Okumura A, Kubota M, Saito Y, Takanashi JI, Hirose S, Yamagata T, Yamanouchi H, Mizuguchi M	Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes.	Brain Dev	34	337-43	2012
Suzukawa M, Morita H, Nambu A, Arae K, Shimura E, Shibui A, Yamaguchi S, Suzukawa K, Nakanishi W, Oboki K, Kajiwara N, Ohno T, Ishii A, Korner H, Cua DJ, Suto H, Yoshimoto T, Iwakura Y, Yamasoba T, Ohta K, Sudo K, Saito H, Okumura K, Broide DH, Matsumoto K, Nakae S	Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F, is crucial for murine asthma	J Immunol	189(7)	3641-3652	2012

別紙4
雑誌

Morita A, Nakahira K, Hasegawa T, Uchida K, Taniguchi Y, Takeda S, Toyoda A, Sakaki Y,Shimada A, Takeda H, Yanagihara I	Establishment and characterization of Roberts syndrome and SC phocomelia model medaka, *Oryzias latipes*	Dev Growth Differ	54(5)	588-604	2012
Kanda A, Sotomaru Y, Shiozawa S, Hiyama E.	Establishment of ES cells from inbred strain mice by dual inhibition (2i).	The Journal of Reproductive Medicine	58	77-83	2012
Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, Ohya Y, Saito H, Matsumoto K	Factors associated with steroid phobia in caregivers of children with atopic dermatitis	Pediatr Dermatol	30(1)	29-35	2013
Kashiwakura JC, Ando T, Matsumoto K, Kimura M, Kitaura J, Matho MH, Zajonc DM, Ozeki T, Ra C, MacDonald SM, Siraganian RP, Broide DH, Kawakami Y, Kawakami T	Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy	J Clin Invest	122(1)	218-228	2012
Yuasa Y, Murakami Y, Nakamura H, Uemura K, Ohge H, Sudo T, Hashimoto Y, Nakashima A, Hiyama E, Sueda T.	Histological loss of pancreatic exocrine cells correlates with pancreatic exocrine function after pancreatic surgery.	Pancreas	41	923-933	2012

別紙4
雑誌

Kobayashi H, Sakurai T, Sato S, Nakabayashi K, Hata K, Kono T.	Imprinted DNA methylation repro-gramming during early mouse em-bryogenesis at the Gpr1-Zdbf2 locus is linked to long cis-intergenic transcrip-tion.	FEBS Lett.	23;586(6):	827-833	2012
Ohno T, Morita H, Arae K, Matsumoto K, Nakae S.	Interleukin-33 in allergy.	Allergy	67	1203-1214	2012
Iehara T, Hiyama E, Tajiri T, Yoneda A, Hamazaki M, Fukuzawa M, Hosoi H, Sugimoto T, Sawada T.	Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?	European Journal of Cancer	48(11)	1707-1712	2012
Kinoshita M, Numata S, Tajima A, Ohi K, Hashimoto R, Shimodera S, Imoto I, Itakura M, Takeda M, Ohmori T.	Meta-analysis of association studies between *DISC1* missense variants and schizophrenia in the Japanese population.	*Schizophr Res*	141(2-3)	271-273	2012
Saitoh M, Shinohara M, Hoshino H, Kubota M, Amemiya K, Takanashi JL, Hwang SK, Hirose S, Mizuguchi M	Mutations of the SCN1A gene in acute encephalopathy.	Epilepsia.	53	558-564	2012
Kawai M, Kusuda S, Cho K, Horikawa R, Takizawa F, Ono M, Hattori T, Oshiro M.	Nationwide surveillance of circulatory collapse associated with levothyroxine administration in very-low-birthweight infants in Japan.	Pediatr Int.	54(2)	177-181	2012

別紙4
雑誌

Nomura I, Morita H, Ohya Y, Saito H, Matsumoto K	Non-IgE-mediated gastrointestinal food allergies: distinct differences in clinical phenotype between Western countries and Japan.	Curr Allergy Asthma Rep	12(4)	297-303	2012
Okayama Y, Kashiwakura J, Sasaki-Sakamoto T, Matsumoto K, Hashimoto N, Ohmori K, Kawakami T, Saito H, Ra C	Omalizumab inhibits acceleration of FcepsilonRI-mediated responsiveness of immature human mast cells by immunoglobulin E	Ann Allergy Asthma Immunol	108(3)	188-194 e182	2012
Koketsu R, Yamaguchi M, Suzukawa M, Arai H, Nagase H, Matsumoto K, Saito H, Ra C, Yamamoto K, Ohta K	Pretreatment with low-levels of FceRI- crosslinking stimulation enhances basophil mediator release.	Int Arch Allergy Immunol		In Press	2013
Sakabe R, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakashima A, Ohge H, Sueda T, Hiyama E.	Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.	Annals of Surgical Oncology	19	3072-3080	2012
Ehara T, Kamei Y, Takahashi M, Yuan X, Kanai S, Tamura E, Tanaka M, Yamazaki T, Miura S, Ezaki O, Suganami T, Okano M, Ogawa Y.	Role of DNA methylation in the regulation of lipogenic glycerol-3-phosphate acyltransferase 1 gene expression in the mouse neonatal liver.	Diabetes	61	2442-2450	2012

別紙4
雑誌

Nakae S, Morita H, Ohno T, Arae K, Matsumoto K, Saito H	Role of Interleukin-33 in innate-type immune cells in allergy.	Allergology Int		In Press	2013
Kojima R, Matsuda A, Nomura I, Matsubara O, Nonoyama S, Ohya Y, Saito H, Matsumoto K	Salivary cortisol response to stress in young children with atopic dermatitis	Pediatr Dermatol	30(1)	17-22	2013
Morita H, Arae K, Ohno T, Kajiwara N, Oboki K, Matsuda A, Suto H, Okumura K, Sudo K, Takahashi T, Matsumoto K, Nakae S	ST2 requires Th2-, but not Th17-, type airway inflammation in epicutaneously antigen- sensitized mice	Allergol Int	61(2)	265-273	2012
Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, Teramoto A, Tatsumi KI, Tachibana K, Katsumata N, Horikawa R.	Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method.	Endocr J.	59(9)	771-780	2012
Watanabe N, Suzuki T, Kitano E, Kitamura H, Hatanaka M, Sago H.	Successful pregnancy in a patient suffering from recurrent mid-trimester miscarriage with C9 deficiency after receiving cervical cerclage followed by clindamycin and progesterone: A case report	JOGR	38(3)	562-566	2012

Tajiri T, Kimura O, Fumino S, Furukawa T, Iehara T, Souzaki R, Kinoshita Y, Koga Y, Suminoe A, Hara T, Kohashi K, Oda Y, Hishiki T, Hosoi H, Hiyama E, Taguchi T.	Surgical strategies for unresectable hepatoblastomas.	Journal of Pediatric Surgery	47	2194–2198	2012
Fujiwara T, Kubzansky LD, Matsumoto K, Kawachi I	The association between oxytocin and social capital.	PLoS One	7	e52018	2012
Nakashima A, Shima T, Inada K, Ito M, Saito S.	The Balance of the Immune System between T Cells and NK Cells in Miscarriage.	Am J Reprod Immunol.	67	304–310	2012
Toldi G., Saito S, Shima T., Halmos A., Veresh Z., Vásárhelyi B., Rigó J., Molvarec A.	The frequency of peripheral blood CD4+ CD25high FoxP3+ and CD4+ CD25− FoxP3+ regulatory T cells in normal pregnancy and preeclampsia.	Am J Reprod Immunol.	68	175–180	2012
Japanese Archipelago Human Population Genetics Consortium, Jinam T, Nishida N, Hirai M, Kawamura S, Oota H, Umetsu K, Kimura R, Ohashi J, Tajima A, Yamamoto T, Tanabe H, Mano S, Suto Y, Kaname T, Naritomi K, Yanagi K, Niikawa N, Omoto K, Tokunaga K, Saitou N.	The history of human populations in the Japanese Archipelago inferred from genome-wide SNP data with a special reference to the Ainu and the Ryukyuan populations.	J Hum Genet	57(12)	787–795	2012

別紙4
雑誌

Watanabe Y, Nakamura T, Ishikawa S, Fujisaka S, Usui I, Tsuneyama K, Ichihara Y, Wada T, Hirata Y, Suganami T, Izaki H, Akira S, Miyake K, Kanayama HO, Shimabukuro M, Sata M, Sasaoka T, Ogawa Y, Tobe K, Takatsu K, Nagai Y.	The Radioprotective 105/MD-1 complex contributes to diet-induced obesity and adipose tissue inflammation.	Diabetes	61	1199-1209	2012
Fujishima H, Okada N, Dogru M, Baba F, Tomita M, Abe J, Matsumoto K, Saito H	The role of Staphylococcal enterotoxin in atopic keratoconjunctivitis and corneal ulceration	Allergy	67(6)	799-803	2012
Nakanishi MO, Hayakawa K, Nakabayashi K, Hata K, Shiota K, Tanaka S.	Trophoblast-specific DNA methylation occurs after the segregation of the tro-phectoderm and inner cell mass in the mouse periimplantation embryo.	Epigenetics	Feb;7(2)	173-182	2012
Hashimoto K, Sakamoto N, Takekoh M, Ikeda N, Kato K, Honda M, Tamai S, Miyamura K, Horikawa R, Ohya Y.	Validity of the Family-Rated Kinder Infant Development Scale (KIDS) for Children.	Journal of Pediatric Rehabilitation Medicine			in press
島田由紀子, 堀川玲子, 有阪治	胎生期性ホルモンの空間認知能への影響を粘土の造形表現からみた検討	ホルモンと臨床58 特集小児内分泌学の進歩2010		1107-1110	2012

別紙4
雑誌

山本晶子, 西垣五月, 水野裕介, 宮下健悟, 野田雅裕, 内木康博, 堀川玲子	ビタミンD欠乏症12例の検討	ホルモンと臨床59 特集小児内分泌学の進歩2011		291-294	2012
亀井康富, 小川佳宏	エピゲノムと糖尿病	最新医学	67(1)	27-31	2012
塩崎有宏, 齋藤滋	腟炎, 頸管炎, 細菌性腟症と早産対策.	産婦人科の実際	61(4)	563-569	2012
米田 哲, 齋藤 滋	リトドリン塩酸塩の後発医薬品から先発医薬品に切り替えて妊娠を継続しえた早産ハイリスク妊婦の2症例.	産婦人科の実際	61(9)	1395-1399	2012
荒田尚子	糖尿病と妊娠に関する最新のエビデンス	プラクティス	29(4)	401-406	2012
荒田尚子, 青木宏明, 左合治彦	妊婦自身の出生体重は妊娠糖尿病や妊娠高血圧症候群の発症やその他の妊娠結果に関連するか?	糖尿病と妊娠	12(1)	85-91	2012
堀川玲子	小児思春期発症摂食障害の現状と予後	最新医学	67(9)	2032-2039	2012

別紙4

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
荒田尚子、村島温子、久保隆彦	合併症妊娠　内分泌代謝・リウマチ疾患（甲状腺疾患、膠原病）	日本周産期新生児医学会教育研修委員会	症例から学ぶ　周産期診療ワークブック	メディカルビュー社	東京	2012	85-90
荒田尚子	妊娠と甲状腺疾患	門脇　孝、下村伊一郎	代謝・内分泌疾患診療　最新ガイドライン	総合医学社	東京	2012	243-245
堀川玲子	思春期早発症	成瀬光栄・平田結喜緒・島津章	内分泌代謝専門医ガイドブック	診断と治療社	東京	2012	271-273
堀川玲子	やせに関連する疾患　鑑別すべき疾患	杉原茂孝	小児科学レクチャー介入すべきポイントがわかる小児の肥満とやせQ&A	総合医学社	東京	2012	1029-1047

研究成果の刊行物・別刷

CLINICAL REPORT

AMERICAN JOURNAL OF medical genetics PART A

Aberrant Methylation of H19-DMR Acquired After Implantation Was Dissimilar in Soma Versus Placenta of Patients With Beckwith–Wiedemann Syndrome

Ken Higashimoto,[1] Kazuhiko Nakabayashi,[2] Hitomi Yatsuki,[1] Hokuto Yoshinaga,[1] Kosuke Jozaki,[1] Junichiro Okada,[3] Yoriko Watanabe,[3] Aiko Aoki,[4] Arihiro Shiozaki,[4] Shigeru Saito,[4] Kayoko Koide,[1] Tsunehiro Mukai,[5] Kenichiro Hata,[2] and Hidenobu Soejima[1]*

[1]Division of Molecular Genetics & Epigenetics, Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga, Japan

[2]Department of Maternal–Fetal Biology, National Research Institute for Child Health and Development, Setagaya, Tokyo, Japan

[3]Department of Pediatrics, Kurume University, Kurume, Japan

[4]Department of Obstetrics and Gynecology, University of Toyama, Toyama, Japan

[5]Nishikyushu University, Kanzaki, Saga, Japan

Manuscript Received: 7 October 2011; Manuscript Accepted: 19 January 2012

Gain of methylation (GOM) at the H19-differentially methylated region (H19-DMR) is one of several causative alterations in Beckwith–Wiedemann syndrome (BWS), an imprinting-related disorder. In most patients with epigenetic changes at H19-DMR, the timing of and mechanism mediating GOM is unknown. To clarify this, we analyzed methylation at the imprinting control regions of somatic tissues and the placenta from two unrelated, naturally conceived patients with sporadic BWS. Maternal H19-DMR was abnormally and variably hypermethylated in both patients, indicating epigenetic mosaicism. Aberrant methylation levels were consistently lower in placenta than in blood and skin. Mosaic and discordant methylation strongly suggested that aberrant hypermethylation occurred after implantation, when genome-wide de novo methylation normally occurs. We expect aberrant de novo hypermethylation of H19-DMR happens to a greater extent in embryos than in placentas, as this is normally the case for de novo methylation. In addition, of 16 primary imprinted DMRs analyzed, only H19-DMR was aberrantly methylated, except for NNAT DMR in the placental chorangioma of Patient 2. To our knowledge, these are the first data suggesting when GOM of H19-DMR occurs.

Key words: Beckwith–Wiedemann syndrome; H19-DMR; aberrant DNA methylation; after implantation

How to Cite this Article:
Higashimoto K, Nakabayashi K, Yatsuki H, Yoshinaga H, Jozaki K, Okada J, Watanabe Y, Aoki A, Shiozaki A, Saito S, Koide K, Mukai T, Hata K, Soejima H. 2012. Aberrant methylation of H19-DMR acquired after implantation was dissimilar in soma versus placenta of patients with Beckwith–Wiedemann syndrome.
Am J Med Genet Part A 158A:1670–1675.

INTRODUCTION

Beckwith–Wiedemann syndrome (BWS) is an imprinting-related condition characterized by macrosomia, macroglossia, and abdominal wall defects (OMIM #130650). The relevant imprinted chromosomal region in BWS, 11p15.5, consists of two independent imprinted domains, *IGF2/H19* and *CDKN1C/KCNQ1OT1*. Imprinted genes within each domain are regulated by two imprinting control regions (ICR), the H19-differentially methylated region (H19-DMR) or KvDMR1 [Weksberg et al., 2010]. Several causative alterations have been identified in patients with BWS: loss of methylation (LOM) at KvDMR1, gain of methylation (GOM) at H19-DMR, paternal uniparental disomy (UPD), *CDKN1C* mutations, and chromosomal abnormality involving 11p15 [Sasaki et al., 2007; Weksberg et al., 2010].

Additional supporting information may be found in the online version of this article.

Grant sponsor: Japan Society for the Promotion of Science; Grant number: 20590330; Grant sponsor: Ministry of Health, Labor, and Welfare; Grant sponsor: National Center for Child Health and Development.

*Correspondence to:
Hidenobu Soejima, M.D., Ph.D., Professor, Division of Molecular Genetics & Epigenetics, Department of Biomolecular Sciences, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
E-mail: soejimah@med.saga-u.ac.jp

Article first published online in Wiley Online Library (wileyonlinelibrary.com): 10 May 2012
DOI 10.1002/ajmg.a.35335

Methylation of H19-DMR is erased in primordial germ cells (PGCs) but becomes reestablished during spermatogenesis [Li, 2002; Sasaki and Matsui, 2008]: this methylation regulates the expression of *IGF2* and *H19* by functioning as a chromatin insulator, restricting access to shared enhancers [Bell and Felsenfeld, 2000; Hark et al., 2000]. GOM on the maternal H19-DMR leads to expression of both *IGF2* alleles and silencing of both *H19* alleles. Dominant maternal transmissions of microdeletions and/or base substitutions within H19-DMR have recently been reported in a few patients of BWS with H19-DMR GOM [Demars et al., 2010]. However, when and how the GOM on the maternal H19-DMR occurs is not clear.

Here, we found epigenetic mosaicism in two BWS patients. We also found that GOM at H19-DMR was discordant in blood and skin versus placenta; specifically, methylation levels were lower in placental samples. These findings strongly suggest that aberrant methylation of H19-DMR occurred after implantation. As a result, we expect aberrant de novo methylation happens to a greater extent in embryos than in placentas.

MATERIALS AND METHODS

Patients

Two unrelated patients with sporadic BWS, Patient 1 (BWS047) and Patient 2 (bwsh21-015), were delivered by cesarean in the third trimester of pregnancy. The mothers of both patients conceived naturally. Patient 1 and Patient 2 met clinical criteria for BWS as described by Elliott et al. [1994] and Weksberg et al. [2001], respectively (Table I). The placenta of Patient 1 was large and weighed 1,065 g, but was without any pathological abnormality. The placenta of Patient 2 was also large, weighing 1,620 g, and had an encapsulated placental chorangioma, as reported previously [Aoki et al., 2011]. The standard G-banding chromosome analysis using peripheral blood samples showed no abnormalities in either patient. This study was approved by the Ethics Committee for Human Genome and Gene Analyses of the Faculty of Medicine, Saga University.

Southern Blot Analysis

Genomic DNA was extracted from embryo-derived somatic tissues and the placentas of the patients (Fig. 1). Methylation-sensitive Southern blots with *Bam*HI and *Not*I were employed for KvDMR1, and blots with *Pst*I and *Mlu*I were employed for H19-DMR, as described previously [Soejima et al., 2004]. Band intensity was measured using the FLA-7000 fluoro-image analyzer (Fujifilm, Tokyo, Japan). The methylation index (MI, %) was then calculated (Fig. 1). Southern blots with *Apa*I were used to identify the microdeletion of H19-DMR as described previously [Sparago et al., 2004].

Bisulfite Sequencing and Combined Bisulfite Restriction Analysis (COBRA)

Bisulfite sequencing covering the sixth CTCF binding site (CTS6) was performed. For COBRA, PCR products of each primary imprinted DMR were digested with the appropriate restriction endonucleases and were then separated using the MultiNA Microchip Electrophoresis System (Shimazdu, Japan). The methylation index was also calculated. All PCR primer sets used in this study have been listed in Supplementary Table SI (See Supporting Information online).

DNA Polymorphism Analyses

For quantitative polymorphism analyses, tetranucleotide repeat markers (*D11S1997* and *HUMTH01*) and a triplet repeat marker (*D11S2362*) from 11p15.4–p15.5 were amplified and separated by electrophoresis on an Applied Biosystems 3130 genetic analyzer (Applied Biosystems, NY); data were quantitatively analyzed with the GeneMapper software. The peak height ratios of paternal allele to maternal allele were calculated. A single nucleotide polymorphism (SNP) for the *Rsa*I recognition site in *H19* exon 5 (rs2839703) was also quantitatively analyzed using hot-stop PCR [Uejima et al., 2000]. Band intensity was measured using the FLA-7000 fluoro-image analyzer (Fujifilm).

Mutation Search of H19-DMR

To search for mutations in the binding sites of CTCF, OCT4, and SOX2, we sequenced a genomic region in and around H19-DMR, which included seven CTCF-binding sites, three OCT4 sites, and one SOX2 site.

TABLE I. Clinical Information of BWS Patients

Patient ID	Conception	Birth weight (gestational age)	Clinical features	Karyotype	Placental weight and pathology	Placental–fetal weight ratio
Patient 1 (BWS047)	Natural	4,506 g (36w2d)	macrosomia macroglossia abdominal wall defect hypoglycemia	46,XY	1,065 g no pathological findings	0.236
Patient 2 (bwsh21-015)	Natural	2,540 g (33w5d)	macrosomia macroglossia hypoglycemia renal malformation hepatosplenomegaly	46,XX	1,620 g placental chorangioma	0.638



FIG. 1. Methylation analyses of KvDMR1 and H19-DMR. A: Methylation-sensitive Southern blots for KvDMR1. Genomic DNA was extracted from the cord blood, peripheral blood, skin, and placenta of Patient 1 and from the cord blood, placenta, and placental chorangioma of Patient 2. Methylation at KvDMR1 was normal in all samples analyzed. Methylation indices (MI, %) are shown under the figure. B: Methylation-sensitive Southern blots for H19-DMR. The MIs of blood samples were higher than the MIs of placental samples. MI was calculated using the equation $[M/(M+U)] \times 100$, where M is the intensity of the methylated band and U is the intensity of the unmethylated band. C: Bisulfite sequencing of H19-DMR in Patient 1. The two parental alleles were distinguishable by differences in SNPs. Both parental alleles were completely methylated in the cord blood, peripheral blood, and skin samples, and the maternal allele, which is normally unmethylated, was partially methylated in the placenta. D: Bisulfite sequencing of H19-DMR in Patient 2. Methylation of the maternal allele was higher in the cord blood than in the placenta or placental chorangioma. These results were consistent with the results of the Southern blot analysis. We confirmed complete methylation of paternal H19-DMR alleles and complete demethylation of maternal H19-DMR alleles in four normal control placentas that were heterozygous for identifiable SNPs (data not shown). Fa, father; Mo, mother; CB, cord blood; PB, peripheral blood; Pl, placenta; Pl-T, placental chorangioma; m, methylated band; um, unmethylated band; *, nonspecific bands; Mat, maternal allele; Pat, paternal allele; CTS6, sixth CTCF binding site; *MluI*, a restriction site approximately 80 bp downstream of CTS6 assayed by methylation-sensitive Southern blot and COBRA.

RESULTS

We first examined the methylation status of the two ICRs, KvDMR1, and H19-DMR, at 11p15.5 using methylation-sensitive Southern blot analysis. Methylation at KvDMR1 was normal in all samples collected (Fig. 1A); however, methylation at H19-DMR was aberrant (Fig. 1B). In Patient 1, hypermethylation at H19-DMR was complete in cord blood and peripheral blood samples (MI = 100%), and hypermethylation in the placenta was partial (MI = 70%). In Patient 2, H19-DMR was partially hypermethylated in cord blood (MI = 90%) but less so in the placenta and placental chorangioma (MI = 71% and MI = 83%, respectively). For further investigation of differences in methylation between the patients' somatic tissues and placentas, the CTS6 site was subjected to bisulfite sequencing (Fig. 1C and D). We could distinguish the two parental alleles in each patient sample using informative SNPs (rs10732516 and rs2071094). The maternal allele, which is normally unmethylated, was completely methylated in the cord blood, peripheral blood, and skin from Patient 1. However, in placental samples from Patient 1, the maternal allele was only partially methylated: 36% of all CpGs analyzed were methylated. Similar results were observed in Patient 2: the maternal allele in the cord blood was 68% methylated; however, the maternal allele was only 31% and 55% methylated in the placenta and chorangioma samples, respectively. The paternal alleles, which are normally fully methylated, were fully methylated in all samples. These findings supported the results of the Southern blots. Furthermore, we could not find any microdeletions or mutations in or around H19-DMR,

including seven CTCF-binding sites, three OCT4 sites, and one SOX2 site, indicating that there was no genetic cause of the hypermethylation (Fig. 2A and data not shown).

Next, we analyzed polymorphic markers at 11p15.4–p15.5 to determine whether copy number abnormalities or paternal UPD might be involved in these BWS patients. Although smaller PCR products were more easily amplified, paternal–maternal allele ratios in blood samples were between 0.92 and 1.33, indicating that both parental alleles were equally represented in both patients (Fig. 2B). Therefore, we could rule out copy number abnormality and paternal UPD within the patients' blood. We also investigated maternal contamination in the placenta. *D11S1997* and *HUMTH01* for Patient 1 and the *Rsa*I polymorphism in *H19* (rs2839703) for Patient 2 were used for this investigation because the mothers were expected to be homozygous for such polymorphisms. Thus, we investigated contamination of our samples by assessing the homozygosity of the polymorphisms in the mothers. The paternal–maternal ratios in Patient 1 were 0.94 and 1.03, indicating an equal contribution of both parental alleles and suggesting no contamination (Fig. 2B). In Patient 2, the ratios were 0.77 and 0.78 in the placenta and chorangioma, respectively, suggesting a small amount of contamination (Fig. 2C). However, such contamination was too



FIG. 2. Microdeletion analysis of H19-DMR, polymorphism analyses, and COBRA of primary imprinted DMRs in embryo-derived and placental samples. A: Southern blots identifying a microdeletion of H19-DMR. A genomic fragment (7.7 kb) generated by *Apa*I digestion, which included the entire H19-DMR, was evident in all samples, indicating that there was no microdeletion in this DMR. B: Microsatellite markers at 11p15.4–p15.5. The peak heights associated with each parental allele in all samples were quantitatively analyzed. The results indicated that both parental alleles were present and equally represented. C: Hot-stop PCR of an *Rsa*I polymorphic site in Patient 2. The ratios of paternal allele to maternal allele are shown under the figure. Although the ratios in the placenta and placental chorangioma are lower than in the cord blood, suggesting a small amount of maternal contamination, this was not enough to affect the results of the methylation analyses. COBRA of cord blood (D) and placentas (E), demonstrating that H19-DMR was hypermethylated. CTS6 is contained within H19-DMR. Methylation at other DMRs was normal in all samples, except for methylation at NNAT, which was aberrant in the placental chorangioma. Cord blood and placentas from 24 normal individuals were used as controls. The upper limit of normal methylation was defined as the higher of these two values: (1) the average of controls + 3 SD, or (2) the average + 15%. Similarly, the lower limit of normal methylation was definite as the lower of these two values: (1) the average of controls − 3 SD, or (2) the average − 15%. The upper and lower limits are indicated by gray bars. ○: Patient 1; △: Patient 2; ◇: placental chorangioma of Patient 2.